At Farmson Basic Drugs, innovation has always been a driving force behind our growth. While we are globally recognised for our leadership in Paracetamol manufacturing, our journey continues as we expand into new, high-demand Active Pharmaceutical Ingredients (APIs). This expansion strengthens our portfolio and allows us to support even more pharmaceutical companies across the world with reliable, quality-driven ingredients.

Our upcoming range of APIs reflects the same core principles that built the Farmson reputation: purity, consistency, compliance, and a deeply integrated manufacturing approach. Each new API is developed with careful attention to global regulatory standards and industry expectations. From sourcing raw materials to designing robust processes, every step is aligned with quality-first thinking.

We have strategically invested in world-class facilities, modern technology, and advanced R&D capabilities to support this API expansion. These facilities are engineered for efficiency, environmental responsibility, and long-term scalability—ensuring we can meet evolving global requirements without compromise.

By adding new APIs to our portfolio, we are also creating greater value for our partners, who can now access multiple essential ingredients from a single, trusted manufacturer. This reduces supply-chain complexity and ensures consistency in documentation, support, and quality systems.

What truly sets Farmson apart is our commitment to transparent operations, dependable supply, and long-term customer partnerships. As we step into new therapeutic categories and broaden our API range, our focus remains on delivering ingredients that meet stringent international standards while supporting the health and well-being of communities worldwide.

With our new API initiatives underway, Farmson continues to move forward with purpose strengthening our capabilities, diversifying our offerings, and carrying our legacy of quality into the future.